A phase II trial of carboplatin and vindesine in patients with non-small cell lung cancer. A Hellenic Cooperative Oncology Group study

Απλή σελίδα τεκμηρίου
dc.contributor.authorPavlidis, N. A.en
dc.contributor.authorKlouvas, G.en
dc.contributor.authorNicolaides, C.en
dc.contributor.authorKarantanas, A.en
dc.contributor.authorBeer, M.en
dc.contributor.authorFountzilas, G.en
dc.date.accessioned2015-11-24T19:39:57Z
dc.date.available2015-11-24T19:39:57Z
dc.identifier.issn0169-5002-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/24283
dc.rightsDefault Licence-
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*therapeutic useen
dc.subjectCarboplatin/administration & dosageen
dc.subjectCarcinoma, Non-Small-Cell Lung/*drug therapyen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectLung Neoplasms/*drug therapyen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectVindesine/administration & dosageen
dc.titleA phase II trial of carboplatin and vindesine in patients with non-small cell lung cancer. A Hellenic Cooperative Oncology Group studyen
heal.abstractIn an effort to investigate a regimen less toxic and more convenient than cisplatin combinations, 50 patients with non-small cell lung cancer (NSCLC) were treated in a Phase II study with carboplatin and vindesine. Carboplatin 300 mg/m2 every 28 days and vindesine 3 mg/m2 every 2 weeks were administered on an outpatient basis. Eight patients had a partial response of their disease (16%, confidence limits 7-29%). Mean duration of response was 4.5+ months (1 +/- 8). Toxicity, mainly of grade I-II, was noticed in 4-28% of the patients. The most common side effect was mild to moderate leukopenia (28%). The combination of carboplatin and vindesine at the above doses was very well tolerated. Although the response rate was relatively low, the survival in this patient population was similar to other cisplatin-containing regimens.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/8069607-
heal.identifier.secondaryhttp://ac.els-cdn.com/016950029390312L/1-s2.0-016950029390312L-main.pdf?_tid=f818a032235bfd4f8222ad6d31c763c2&acdnat=1333613150_82fa7e32cb882886bdc91392e6bbb319-
heal.journalNameLung Canceren
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1993-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ